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Abstract 
Background: Although numerous studies and metanalysis have shown the beneficial effect of statin therapy in CVD 
secondary prevention, there is still controversy such the use of statins for primary CVD prevention in patients with 
DM. The purpose of this study was to evaluate the occurrence of total major adverse cardio-vascular events (MACE) in 
a cohort of patients with type 2 diabetes complicated by nephropathy treated with statins, in order to verify real life 
effect of statin on CVD primary prevention.
Methods: We conducted an observational prospective multicenter study on 564 patients with type 2 diabetic 
nephropathy free of cardiovascular disease attending 21 national outpatient diabetes clinics and followed them up 
for 8 years. 169 of them were treated with statins (group A) while 395 were not on statins (group B).
Results: Notably, none of the patients was treated with a high-intensity statin therapy according to last ADA position 
statement. Total MACE occurred in 32 patients from group A and in 68 patients from group B. Fatal MACE occurred 
in 13 patients from group A and in 30 from group B; nonfatal MACE occurred in 19 patients from group A and in 38 
patients from group B. The analysis of the Kaplan–Meier survival curves showed a not statistically significant difference 
in the incidence of total (p 0.758), fatal (p 0.474) and nonfatal (p 0.812) MACE between the two groups. HbA1c only 
showed a significant difference in the incidence of MACE between the two groups (HR 1.201, CI 1.041–1.387, p 0.012).
Conclusions: These findings suggest that, in a real clinical setting, moderate-intensity statin treatment is ineffective 
in cardiovascular primary prevention for patients with diabetic nephropathy.
Trial registration ClinicalTrials.gov Identifier NCT00535925. Date of registration: September 24, 2007, retrospectively 
registered
Keywords: CVD, Primary prevention, Statin, Diabetes, Nephropathy
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Cardiovascular Diabetology
*Correspondence:  ferdinando.sasso@unina2.it 
1 Department of Internal and Experimental Medicine ‘‘Magrassi-Lanzara’’, 
Second University of Naples, Naples, Italy
Full list of author information is available at the end of the article
Page 2 of 10Sasso et al. Cardiovasc Diabetol  (2016) 15:147 
Background
There is a strong correlation between diabetes mellitus 
(DM) and cardiovascular disease (CVD). Cardiovascu-
lar complications account for 50–80  % of early deaths 
in diabetes patients. A large Danish study [1] showed 
that patients with DM and no prior myocardial infarc-
tion (MI) exhibited a 20 % cardiovascular death risk over 
a 7  years period, which is comparable to those without 
diabetes but prior MI. Moreover, people with type-2 
diabetes (T2DM) are two to four times more likely to 
develop coronary artery disease, cerebrovascular dis-
ease and peripheral vascular disease [2, 3], compared to 
the general population. According to the World Health 
Organization, CVDs are the leading cause of death glob-
ally [4] and accelerated atherosclerosis is the cause of the 
majority of cardiovascular events [5]. The most recent 
guidelines of the European Society of Cardiology (ESC) 
state that people with type 2 diabetes are automatically at 
high CV risk. Moreover subjects with diabetes and target 
organ damage such as proteinuria, are at very high CV 
risk [6]. Therefore, diabetic nephropathy, which repre-
sents a major form of chronic kidney disease and a lead-
ing cause of end-stage renal disease, is also a risk factor 
for CVD [7]. The underlying pathogenic mechanism that 
links diabetic nephropathy to a high risk of CVD remains 
unclear. This is probably associated to endothelial dam-
age through inflammation and oxidative stress. Moreo-
ver advanced glycation end products may play a role in 
the development and progression of atherosclerosis in 
patients with diabetic nephropathy [8]. Several studies 
have shown that diabetic nephropathy is a prognostic 
indicator of early mortality from CVD independently on 
the mechanisms involved in its development [9].
In people with DM, intracellular hyperglycaemia has 
been shown to lead to the generation of advanced gly-
cation end-products and reactive oxygen species which 
might activate a number of pro-inflammatory path-
ways, induce endothelial dysfunction, cause long-lasting 
modifications of the arterial wall and enhance insulin 
resistance [10–12]. These pathways contribute to the 
development of the atherogenic dyslipidaemia in diabe-
tes, characterized by high serum triglycerides (TG), high 
small dense low-density lipoprotein cholesterol (LDL-C) 
levels and low high-density lipoprotein cholesterol (HDL-
C) levels [13, 14]. Hyperlipidaemia is a significant modifi-
able risk factor that can be targeted. With this regard the 
latest statement of the American Diabetes Association 
(ADA) recommends lifestyle intervention to improve 
the lipid profile in patients with DM and initiate statin 
therapy for patients with overt CVD (level of evidence 
A), those aged 40–75  years regardless of additional CV 
risk factors (level of evidence A) and those aged below 
40 years with additional risk factors (level of evidence C) 
[15]. Although numerous studies and metanalysis have 
shown the beneficial effect of statin therapy in CVD sec-
ondary prevention [16–19], there is still controversy such 
the use of statins for primary CVD prevention [20–23] in 
patients with DM.
Moreover few clinical trials showed uncertainty 
around statin therapy in people with DM as the effects 
on particular CV outcomes could be influenced by other 
factors, such as blood pressure and glycaemic con-
trol [24]. There is a lack of evidence in the role of sta-
tin treatment of selected categories of diabetic patients 
at very high CV risk, such as those affected by diabetic 
nephropathy. There is also the need for awareness of 
risks as well as benefits  around the use of this class of 
medications for CV primary prevention, especially their 
potential for adverse effects [25] and their safety in older 
patients [26].
Methods
Aim, design and setting of the study
We evaluated the use of statins in a cohort of patients 
with T2DM complicated by nephropathy, in order to ver-
ify the effects for CVD primary prevention in this high 
risk population.
We conducted an observational prospective multi-
center study on a subgroup of type 2 diabetes patients 
from the NID-2 study cohort [27], selecting for the spe-
cific purpose of the current study only patients free of 
CVD at baseline. CVD included: coronary artery disease 
(MI, angioplasty, coronary bypass graft), cerebrovascu-
lar disease (TIA, stroke) and peripheral vascular dis-
ease (occlusive arteries disease, revascularisation, major 
amputation).
The NID-2 study recruited 847 patients with type 2 
diabetes at very high CV risk, complicated by diabetic 
nephropathy III–IV stage (diagnosed by clinical criteria, 
i.e., micro/macro-albuminuria and moderate/severe dia-
betic retinopathy) from 21 clinics of secondary diabetes 
care in Southern Italy.
The following inclusion criteria were taken into 
account: T2DM, age  ≥40  years, therapy with diet and/
or oral hypoglycaemic agents during the first 3  years 
of the diagnosis of diabetes, persistent albuminu-
ria  ≥30  mg/24  h and moderate/severe diabetic retin-
opathy. Exclusion criteria were: type 1 diabetes, type 2 
diabetes diagnosed below the age of 30 years or recently 
diagnosed in the last 3  months, insulin therapy during 
the first 3 years of diagnosis of the disease, severe liver or 
heart failure and known neoplastic or psychiatric disease.
Baseline information collected during the first visit, for 
screening and enrolment, included past medical history, 
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with particular reference to major CV events (myocardial 
infarction and stroke), blood pressure measurement (cal-
culated as a mean of three measurements taken in a sit-
ting position after 10 min of rest), height and body weight 
as well as laboratory and therapeutic features. Laboratory 
tests were performed locally and included glycaemic, 
lipidic and renal function assessment. GFR was calcu-
lated by the four variable Modification of Diet in Renal 
Disease equation and albuminuria was measured on 24-h 
urine collection.
Active follow-up, with control visits planned every 
6  months, was completed on 30 November 2013. 
In particular, adherence to therapy was assessed by 
questionnaire.
When a CV event was suspected, hospital records were 
collected to make the diagnosis according to the Euro-
pean Society of Cardiology. Death certificates and autopsy 
reports were used to establish the underlying cause of 
death and to identify CV deaths, through the ninth revi-
sion of the International Classification of Diseases.
Characteristics of participants
We selected 564 patients free from CVD from this 
cohort.
169 of them were treated with statins (group A) while 
395 of them were not on statins (group B). Both groups 
were homogeneous for age, BMI, HbA1c, blood pres-
sure, lipid profile, albumin excretion rate (UAlb) and car-
diovascular risk. Patients were followed up for 8  years, 
with control visits planned every 6 months. The choice of 
specific type and dose of statin was independently made 
by each individual physician for any patient, according 
to the personal clinical judgment. Moreover, the choice 
of introducing statin in the therapy was independently 
made by the physician, according to his/her perception 
and valuation of the CV risk in patients at primary CV 
prevention. The target for all patients was a LDL-choles-
terol  <100  mg/dl, according to previous ADA position 
statement [28].
Outcomes
Primary outcome was total major adverse cardiovascular 
events (MACE), defined as CV death, nonfatal myocar-
dial infarction and nonfatal stroke. Secondary outcomes 
were, separately, fatal and nonfatal CV events.
Twenty-one outpatient clinics in Campania region of 
Italy (a geographic area characterized by a homogene-
ous prevalence of type 2 diabetes) were randomly cho-
sen among all the regional clinics. In the design and 
implementation process, any effort was made to ensure 
consistency across the 21 centers in terms of data specifi-
cation, data collection tools, and methods and the analy-
sis and reporting of results.
Statistical analysis
Kaplan–Meier survival curves were used to compare 
cumulative probability of time free from MACE. The 
comparison between the two groups was performed 
using the log-rank test. To assess the independent effect 
of CV risk factors on the primary endpoint, hazard ratio, 
with 95 % confidence intervals (HR, 95 % CIs), was esti-
mated by a Cox regression model with demographics 
(age and gender) and several potentially treatable risk 
factors (HbA1c, systolic blood pressure, total cholesterol, 
statin treatment) variables as covariates. Statistical sig-
nificance was fixed at 0.05. Statistical analyses were per-
formed using SPSS version 16.0 (SPSS Inc, Chicago, IL, 
USA) software package.
Results
Patients had a mean age of 64.7  ±  8.8  years and were 
mostly females (55.1  %). They were mainly over-
weight (BMI 29.3  ±  4.6  kg/m2) and not at target 
according to ADA guidelines [15] for glycaemic con-
trol (HbA1c 7.4  ±  1.3  %) and systolic blood pressure 
(135.9 ± 13.2 mmHg). The diastolic blood pressure was 
78.2 ± 7.3 mmHg, total cholesterol was 196 ± 41.2 mg/
dl, LDL cholesterol was 118.7 ± 31.3 mg/dl and triglyc-
erides were 149.3 ± 80.8 mg/dl. More than a quarter of 
the patients were smokers (25.7  %). Cardiovascular risk 
factors and drug treatments, except for statin therapy, 
were not statistically different among the group A and B 
at baseline. Detailed clinical characteristics of all subjects 
at baseline are summarized in Table 1.
Most intriguingly, none of the patients was treated 
with a high-intensity statin therapy (e.g. atorvastatin 
40–80  mg and rosuvastatin 20–40  mg daily) despite to 
the 2016 ADA position statement [15].
Therefore, the subjects of group A received one of the 
following: atorvastatin 10–20 mg, rosuvastatin 5–10 mg, 
simvastatin 20–40 mg, pravastatin 40–80 mg, Lovastatin 
40 mg, fluvastatin 80 mg.
We registered 7 non CV deaths, 3 in group A (malig-
nant neoplasms) and 4 in group B (3 malignant neo-
plasms and 1 accident).
Total MACE occurred in 32 patients (2.37  events/ 
100  pts/year) from group A and 68 patients (2.15   
events/100  pts/year) from group B. 13 fatal MACE 
(0.96  events/100  pts/year) and 19 nonfatal MACE 
(1.4  events/100  pts/year) occurred in group A. 30 fatal 
MACE (0.94 events/100 pts/year) and 38 nonfatal MACE 
(1.2 events/100 pts/year) occurred in group B. Notably, the 
distribution of MACE (fatal and not) was homogeneous 
among the centers and not clustered in just some of them.
The analysis of the Kaplan–Meier survival curves 
showed a not statistically significant difference in the inci-
dence of total MACE in the two groups (p 0.758) (Fig. 1).
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Moreover, no differences were observed between the 
two groups in the analysis of the secondary end points. 
In fact, the analysis of the Kaplan–Meier curves showed 
a not statistically significant difference in the incidence of 
both fatal and nonfatal MACE between the two groups 
(respectively p 0.474 and p 0.812).
To assess the independent effect of the CV risk factors 
on the primary end point, hazard ratio, with 95  % CIs, 
was estimated by a Cox regression model with demo-
graphics (gender) and several potentially treatable risk 
factors variables (smoking, statin therapy, HbA1c, sys-
tolic blood pressure, BMI and total cholesterol) as covari-
ates (Table 2). HbA1c only showed a significant difference 
in the incidence of MACE between the two groups (HR 
1.201, CI 1.041–1.387, p 0.012).
At the end of the follow up 6 % of subjects from group 
A and 5  % from group B were at target for major CV 
risk factors (BMI, glycaemic control, blood pressure, 
lipid profile and UAlb). Moreover more than one half 
of patients treated with statins were at target for LDL-
cholesterol (118; 77 %) and HDL-cholesterol (110; 72 %), 
whereas 159 (44 %) and 155 (43 %) patients not treated 
with a statin where at target for LDL- and HDL-choles-
terol respectively (Fig. 2).
In detail, at the end of 8 years of follow-up no sig-
nificant difference between group A and B was shown 
in BMI (29.8  ±  4.5 vs 29.4  ±  4.9; p 0.35), HbA1c 
Table 1 Demographic and clinical characteristics in patients at baseline in overall cohort and in groups A and B
Values are mean ± SD, or percent
GFR estimated glomerular filtration rate using MDRD calculator, HDL high density lipoprotein, LDL low-density lipoprotein, UAlb urinary albumin excretion, OHA oral 
hypoglycaemic agents
* (p group A vs group B)
Overall (n 564) Group A (n 169) Group B (n 395) p*
Gender (% m/% f ) 44.9/55.1 43.5/56.5 45.1/54.9 0.22
Age (years) 64.7 ± 8.8 64.4 ± 8.4 65.2 ± 9.2 0.21
Duration of diabetes (years) 9.0 ± 4.1 9.2 ± 4.5 8.9 ± 4.0 0.19
Smoker (%) 25.7 26.4 25.2 0.18
BMI (kg/m2) 29.3 ± 4.6 29.6 ± 4.4 29.2. ± 4.7 0.32
HbA1c (%) 7.4 ± 1.3 7.4 ± 1.4 7.5 ± 1.0 0.26
SBP (mmHg) 135.9 ± 13.2 134.6 ± 15.6 136. ± 16.1 0.21
DBP (mmHg) 78.2 ± 7.3 77.5 ± 6.2 79.9 ± 7.0 0.27
Tot. cholesterol (mg/dl) 196 ± 41.2 198.4 ± 43.6 195.4 ± 40.5 0.19
HDL-C (mg/dl) 48.8 ± 11.9 48.9 ± 12,4 48.4 ± 11.7 0.25
LDL-C (mg/dl) 118.7 ± 31.3 119.5 ± 32.5 117.6 ± 30.9 0.16
Triglycerides (mg/dl) 149.3 ± 80.8 146.9 ± 83.4 150.1 ± 81.7 0.17
UAlb (mg/24 h) 143.1 ± 136.3 139.5 ± 140.4 144.4 ± 131.5 0.12
GFR (mL/min/1.73 m2) 66.4 ± 24.3 66.1 ± 28.1 67.2 ± 25.2 0.22
Anti-hypertensive drugs (%) 84.5 % 83.5 85.3 0.19
OHA (%) 67.7 66.5 68.3 0.20
Insulin (%) 29.4 30.1 28.8 0.18
Statins (%) 29.9 100 0
Aspirin and/or other antiplatelet drug (%) 42.8 43.1 42.5 0.24
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Fig. 1 Kaplan–Meier estimates of total major adverse CV events in 
statin-treated group (green line) and non-statin-treated group (blue 
line), during the average follow-up of 8 years
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(7.8  ±  1.6 vs 7.9  ±  1.7; p 0.20), systolic blood pres-
sure (137.6  ±  17.9 vs 138.4  ±  18.5; p 0.28), diastolic 
blood pressure (79.2  ±  7.3 vs 80.1  ±  6.9; p 0.25), tri-
glycerides (156.2 ±  74.7 vs 161.1 ±  81.1; p 0.14), UAlb 
(148.3  ±  145.1 vs 158.8  ±  145.2; p 0.09) and GFR 
(55.3  ±  29.4 vs 56.4  ±  30.1; p 0.18). Conversely, a sig-
nificant difference was observed between two groups in 
total cholesterol (179.8 ± 37.2 vs 206.2 ± 43.7; p 0.036), 
HDL-cholesterol (49.9 ± 11.9 vs 44.2 ± 14.5; p 0.028) and 
LDL-cholesterol (102.7 ± 28.9 vs 138.5 ± 38.3; p 0.011).
Discussion
CVDs are the primary cause of mortality and morbidity 
globally and produce immense health and economic bur-
dens [29]. This prospective and multicenter study shows 
the lack of CV protective effect of statin treatment in 
primary prevention in a T2DM population at very high 
CV risk, such as our cohort with clinical diagnosis of dia-
betic nephropathy (based on the concomitant presence 
of abnormal albuminuria and severe retinopathy). The 
CV outcome has never been evaluated for this high-risk 
population, but the cross-sectional phase of the NID-2 
study pointed out that this category of patients showed 
a 10-year risk of CV events greater than 10  % [30]. In 
patients with T2DM and nephropathy the interaction 
between albuminuria and GFR is statistically significant, 
and it influences the risk for fatal and non-fatal CV events 
[30]. Moreover, both GFR and albuminuria have a great 
influence on CVD burden, independently of the clas-
sification system used for CKD in T2DM [31]. A recent 
large retrospective study on about 58,000 T2DM patients 
based on a UK primary care database confirms that all-
cause mortality and the risk of cardiovascular events 
significantly increase with the decrease of GFR values 
Table 2 Independent effect of  the CV risk factors on  the 
primary end point
HR CI 95 % p
Lower limit Upper limit
Age 1.017 0.994 1.039 0.145
Male gender 0.858 0.538 1.367 0.519
BMI (kg/m2) 1.014 0.972 1.057 0.524
HbA1C (%) 1.201 1.041 1.387 0.012
Total cholesterol (mg/dl) 1.001 0.996 1.006 0.817
Systolic blood pressure 
(mmHg)
1.003 0.988 1.018 0.703
GFR (ml/min) 0.988 0.979 0.998 0.114
UAlb (mg/24 h) 1.000 1.000 1.001 0.502
Statin (yes/no) 0.759 0.496 1.161 0.204
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*
Fig. 2 Rate of patients of both groups at target for major CV risk factors at ending of follow-up (8 years)
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[32]. Therefore, a careful management of GFR, albuminu-
ria and CV risk factors represents a winning strategy to 
reduce the risk of fatal and non fatal CV events.
In this particular study we have only considered the 
population in primary CV prevention according to the 
above-mentioned inclusion criteria. It is very interest-
ing to note that, according to 2014 ADA guidelines 
[28], the main aim for statin treatment was to gain the 
LDL-cholesterol target (<100 mg/dl in primary CV pre-
vention,  <70  mg/dl in secondary CV prevention), inde-
pendently on the dose and the drug chosen.
The most recent ADA guidelines [15] recommend life-
style modification to improve the lipid profile in patients 
with diabetes, and suggest an addition of high-intensity 
statin therapy for patients of all ages with diabetes and 
overt CVD (level A of evidence). Moreover, for primary 
CVD prevention diabetes patients should be treated with 
statins if they are aged over 40  years regardless of CV 
risk factors. In particular, for patients with diabetes aged 
40–75  years with additional atherosclerotic cardiovas-
cular disease risk factors (e.g. LDL cholesterol >100 mg/
dl, high blood pressure, smoking, albuminuria, and fam-
ily history of premature CVD), high-intensity statin and 
lifestyle therapy should be used (level B of evidence). 
According to the position statement of ADA, a high-
intensity statin therapy (e.g. atorvastatin 40–80  mg and 
rosuvastatin 20–40  mg daily) reduces LDL cholesterol 
by >50 % [15].
These Guidelines were based on the observation of the 
effectiveness of specific doses of statins against placebo 
or other statins, rather than aiming at specific LDL cho-
lesterol levels [33]. Thus, the ADA considers the patients 
with increased cardiovascular risk similarly to those with 
known CVD.
Notably, all patients of our cohort (group A) were 
treated with a moderate-intensity statin.
Because of the high rate of patients at target for LDL-
cholesterol in group A, it seems evident that, in this 
observational study, all physicians followed the old “treat 
to target” method rather than the recent ADA position 
statement. Actually, we can state that, independently on 
the dose and kind of the statin used, physicians appropri-
ately prescribed statins to the group A individuals.
Actually, evidence for the efficacy of statins is domi-
nated by randomized controlled trials mostly focused 
on general population at high CV risk or on CVD sec-
ondary prevention [16–19]. However, there is still some 
controversy such the use of statins in diabetes patients 
for primary CVD prevention [20–23] and most of the tri-
als are not specifically designed for selected categories of 
diabetic patients. All the statin clinical trials on diabetic 
populations examined patients with unspecific proteinu-
ria. Our study is focused on type 2 diabetes complicated 
by diabetes nephropathy stricto sensu. A recent review 
[34], supporting the use of statins in primary CV preven-
tion, showed that statins significantly reduce the risk of 
myocardial infarction, coronary death, coronary revas-
cularisation and the risk of stroke in patients with docu-
mented diabetes at baseline irrespective of a prior history 
of vascular disease. However, the absolute risk for people 
with diabetes was probably affected by the entry criteria 
of the trials, so the observed absolute benefits of statin 
cannot be directly extended to any categories of people 
with diabetes but have to be evaluated case by case.
A meta-analysis pooled the data from eight rand-
omized trials that compared statins with placebo in pri-
mary prevention in populations at increased CV risk 
and found that total mortality was not reduced by statins 
[20]. Similarly, another meta-analysis showed that treat-
ment with lipid lowering drugs in primary prevention 
lasting 5–7 years reduced coronary heart disease events 
and mortality by about 30 % but their effect on all-cause 
mortality was not significant [35]. Moreover, a recent lit-
erature-based meta-analysis of 11 randomized controlled 
trials involving 65,229 participants did not find evidence 
for the benefit of statin therapy on all-cause mortality in a 
high-risk primary prevention set-up [36].
The most recently published Cochrane systematic 
review on statins for the primary prevention of CBD 
[37], included 18 randomised controlled trials (56,934 
patients), dating from 1994 to 2008, that compare statins 
with usual care or placebo. All-cause mortality and fatal 
and non-fatal CVD events were reduced with the use of 
statins as it was the need for revascularisation (coronary 
artery bypass graft or angioplasty). Of these trials, only 4 
included patients with diabetes: ASPEN, CARDS, MRC/
BHF Heart Protection Study and CERDIA. The main 
outcome of CERDIA [38] was to determine the effect of 
statin therapy on the progression of carotid intima-media 
thickness, so only the other three have as main outcome 
the effects of statins in major vascular events.
The MRC/BHF Heart Protection Study is a large 
randomised placebo-controlled trial [39], conducted 
between 1994 and 1997, which recruited 2912 patients 
with diabetes (type 1 and type 2) without any diagnosed 
coronary or other occlusive arterial disease at study 
entry, of whom 50 % were allocated to simvastatin 40 mg. 
It showed a highly significant (nearly 30 %) proportional 
reduction of the first major vascular event in the group 
treated with simvastatin compared to the placebo. How-
ever, among the diabetic patients in CDV primary pre-
vention, the absolute risk of major vascular events was 
influenced to a lesser extent by their initial concentra-
tions of LDL-cholesterol as a 1.0  mmol/L reduction in 
LDL cholesterol would translate into avoidance of major 
vascular events during 5  years in about 3  % individuals 
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compared to about 9 % in people with diabetes in CVD 
secondary prevention.
The West of Scotland Coronary Prevention Study 
(WOSCOPS) was the first trial to demonstrate a signifi-
cant 31 % reduction in CV events for primary prevention 
in patients treated with statin therapy for 5  years [40]. 
The twenty-year follow-up of the WOSCOPS further 
suggested that treatment with a statin for 5 years might 
provide a persistent reduction in CVD mortality and hos-
pitalizations, but no impact on stroke [41]. The AFCAPS 
study compared lovastatin with placebo for primary CV 
prevention in a population who had average total cho-
lesterol and LDL-C and below-average HDL-C. After a 
5 years follow up, treatment with lovastatin resulted in a 
37 % reduction in the risk for first fatal or nonfatal acute 
major coronary events [42]. Compared to our results and 
those of the other trials on statin treatment in primary 
prevention, the WOSCOPS and the AFCAPS recruited 
a relatively younger population (mean age around 
55–58  years) and only 1–2  % had a diagnosis of DM. 
Moreover the WOSCOPS recruited only males and with 
higher mean LDL cholesterol levels (192 mg/dl) and the 
AFCAPS excluded those managed with insulin.
Notably, although diabetic patients in our study had a 
mean BMI of 29.3 kg/m2, they did not experience a sig-
nificant survival benefit from the prescription of statins 
before MI, unlike observed in overweight patients with 
diabetes elsewhere [43].
Statin treatment failed to show a positive effect on 
primary CV prevention in our cohort of high CV risk 
patients as shown by 18.9  % MACE, although partially 
related to the concomitant nephropathy. These find-
ings are similar to those found in the Atorvastatin Study 
for Prevention of Coronary Heart Disease Endpoints in 
Non-Insulin-Dependent Diabetes Mellitus (ASPEN). In 
this study 2400 type 2 diabetic patients, of whom 1905 
without prior myocardial infarction, were randomized to 
atorvastatin or placebo and were followed up for 4 years. 
Primary composite end point (CV death, nonfatal myo-
cardial infarction, nonfatal stroke, recanalization, coro-
nary artery bypass grafting, resuscitated cardiac arrest, or 
worsening or unstable angina requiring hospitalization) 
was not significantly different between the two groups 
[44]. These results are further supported by other RCTs, 
such as the CARDS study which enrolled T2DM patients 
aged 40–75 years with no documented previous history 
of cardiovascular disease and at least an additional CV 
risk factor (retinopathy, albuminuria, current smoking or 
hypertension). After 3.9  years of follow-up, atorvastatin 
treatment showed a significant reduction of MACE, but 
didn’t record a significant fall in all-cause mortality [45]. 
Notably, in these two studies atorvastatin was used at 
high-intensity doses.
In the Anglo-Scandinavian Cardiac Outcomes Trial 
(ASCOT) over 19,000 hypertensive patients and with at 
least three additional CV risk factors were randomized 
to receive amlodipine or atenolol. The lipid-lowering 
arm (LLA) of the trial randomized a subgroup of patients 
to additional treatment with atorvastatin or placebo, 
of whom 2532 were classified as having type 2 diabe-
tes. After 3  years of follow-up there was a significant 
reduction in MACEs among the patients allocated on 
atorvastatin, although these reductions were not statisti-
cally significant in the DM subgroup [46]. Moreover the 
11-year mortality follow-up of the lipid-lowering arm in 
the UK confirmed any significant reduction of CV deaths 
[47].
PROSPER was a controlled, randomized study involv-
ing around 6000 patients aged over 70 years, with a his-
tory of or risk factors for CVD. During the 3  years of 
follow-up, pravastatin reduced the risk of fatal and non-
fatal CVD, but did not affect the risk of stroke and did 
not demonstrate a reduction in mortality [48]. Moreover 
the extended follow up over 8.6 years found no evidence 
that treatment of older high-risk subjects with pravasta-
tin for several years prolonged life expectancy as it failed 
to show any reduction in stroke or all-cause mortality 
[49]. The Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial (ALLHAT-LLT) was 
a multicenter study conducted in 10,355 hypertensive 
patients with mean age of 66  years, of whom 14  % had 
a history of CVD and 25 % had T2DM. After a follow up 
of 3.3 years, reduction in all-cause mortality or CVD was 
not significant in the group treated with Pravastatin com-
pared with usual care [50].
Our study shared similar baseline characteristics of 
the population recruited in the above trials, especially 
with regard to the glycaemic control (HbA1c  <  10  %), 
blood pressure (<140/80  mmHg), BMI (<30  kg/m2) and 
LDL (<130 mg/dl). We had a higher percentage of smok-
ers (26  %) and females (55  %). Moreover we recruited 
patients with clinically detected diabetic nephropathy. 
The CARDS was the only study that mentioned 17 % of 
their diabetic population had micro- or macroalbumi-
nuria. The ASCOT and ALLHAT included hypertensive 
patients whereas the PROSPER recruited an older pop-
ulation (mean age 75  years). Compared to our cohort, 
the Heart Protection Study recruited patients with both 
type 1 and type 2 diabetes and shorter disease dura-
tion (<5  years), better glycaemic control (mean HbA1c 
7 %) and better renal function (mean baseline creatinine 
88 µmol/L).
From these studies appeared that the impact of statins 
on CV outcomes in diabetic patients is different between 
primary and secondary prevention. In particular the 
findings from studies in primary prevention were not 
Page 8 of 10Sasso et al. Cardiovasc Diabetol  (2016) 15:147 
obtained by high-intensity statin. Therefore, the recent 
ADA position statement seems to be not supported by 
experimental evidence (level B).
More studies are required about unknown actions 
and overall actions of statins, regarding to potential side 
effects of statin use for short-term [51] and, particularly, 
extended periods [52].
Conclusions
Our study originally showed:
1. The consolidated habit of physicians to use as goal of 
therapy the achievement of the LDL-C target;
2. The difficulties in making as targets all risk factors 
and, hence, the failure to control the residual risk;
3. Lack of effectiveness of traditional therapy with a sta-
tin alone on primary prevention in high-risk individ-
uals.
The main methodological limitation of this study is its 
observational nature. Moreover, since this study is not 
a RCT, the sample size was not preliminary measured, 
and in particular it has insufficient statistical power. On 
the other hand, the cohort was recruited from 21 cent-
ers and the mean follow up was at 8 years. Therefore, in 
this investigation a population at high CV risk was regu-
larly followed for long time by expert specialists at a large 
number of diabetic clinics according to good medical 
practice. In this way, we trust that these conditions were 
modeled on real life and our findings were not “doped” 
by the trial effect occurring in RCTs. In particular we 
observed a great dichotomy between the new guidelines 
and the medical practice in patients at high risk in pri-
mary CV prevention.
Our study shows the inefficacy of statin therapy for 
primary CVD prevention in patients with T2DM and 
clinically detected diabetic nephropathy. These findings 
could be due to the moderate-intensity statin therapy 
used by physicians. Actually, physicians choose type and 
dose of statin using a “treat to target” method referred to 
LDL-cholesterol, without respecting the recent position 
statement of ADA. This therapeutic choice could prob-
ably explain the lack of difference in the incidence of total 
MACE between the two groups, despite the achievement 
of the “classic” targets for LDL- and HDL-cholesterol 
levels in a higher percentage of the statin treated group. 
Additionally, all the other major CV risk factors were at 
target in less than 10  % of patients regardless of statin 
treatment. These findings confirm that although statins 
are effective for the reduction of the incidence of fatal 
and non-fatal MI, the residual global CV risk remains 
high, as people with diabetes have multiple modifiable 
risk factors not influenced by this class of medications. 
Current guidelines on statin treatment for primary CV 
prevention do not apply to the “real life” high risk dia-
betic population of our study and, as such, these guide-
lines would need a strong implementation in clinical 
practice. A long-term targeted multifactorial interven-
tion trial has to be considered in order to try to reduce 
significantly the residual risk in diabetic population in 
primary CV prevention, because this is a major challenge 
for the clinicians as well as national health systems.
Abbreviations
CVD: cardiovascular disease; DM: diabetes mellitus; MACE: major adverse 
cardiovascular events; MI: myocardial infarction; ADA: American Diabetes 
Association; GFR: glomerular filtration rate using; HDL: high density lipopro-
tein; LDL: low-density lipoprotein; UAlb: urinary albumin excretion; OHA: oral 
hypoglycaemic agents.
Authors’ contributions
FCS wrote the manuscript and researched data. GP and PC reviewed/edited 
the manuscript. NL, RaM, OC, LDN and RoM contributed to the discussion and 
performed the statistical analysis. AA, TS and MR, researched data and contrib-
uted to the discussion. All authors read and approved the final manuscript.
Author details
1 Department of Internal and Experimental Medicine ‘‘Magrassi-Lanzara’’, 
Second University of Naples, Naples, Italy. 2 School of Life and Health Sciences, 
Aston University, Birmingham, UK. 3 Unit of Nephrology, Second University 
of Naples, Naples, Italy. 4 Department of Geriatrics and Metabolic Diseases, 
Second University of Naples, Naples, Italy. 5 Department of Advanced Biomedi-
cal Science, University of Naples Federico II, Naples, Italy. 
Acknowledgements
NID-2 (Nephropathy In Diabetes-type 2) Study Group members: F. C. Sasso, O. 
Carbonara, R. Torella, R. D’Urso, A. Lampitella Jr, N. Lascar, R. Nasti, A. Pagano, 
E. Pisa, L. Zirpoli, F. Zibella, U. Amelia, M. Corigliano, G. Conte, L. De Nicola, R. 
Minutolo, P. Trucillo, U. Amelia, P. Calatola, G. Corigliano, E. Del Vecchio, N. De 
Rosa, G. Di Giovanni, A. De Matteo, A. Gatti, S. Gentile, L. Gesuè, L. Improta, A. 
Lampitella, A. Lanzilli, S. Masi, P. Mattei, V. Mastrilli, P. Memoli, M. Pentangelo, E. 
Rossi, S. Sorrentino, R. Troise, A. A. Turco, S. Turco.
Competing interests
The authors declare that they have no competing interests.
Availability of data and material
Sasso FC had full access to all of the data in the study and takes responsibility 
for the integrity of the data and the accuracy of the data analysis.
Consent for publication
All the patients gave their written informed consent for publication of per-
sonal information in a Scientific Journal, without his/her name attached.
Ethics approval and consent to participate
The study was approved by the Ethical Committee of the Second University 
of Naples, Italy.
All the patients gave their written informed consent for the collection and 
analysis of the data.
Funding
This work was partially supported by an Italian Government grant from M.I.U.R. 
(Ministero della Istruzione, Università e Ricerca) (Grant No. PRIN 2007) Rome, 
Italy. The study sponsor had no role in the design of the study and collection, 
analysis, and interpretation of data and in writing the manuscript and in the 
decision to submit the paper for publication.
Received: 12 June 2016   Accepted: 30 September 2016
Page 9 of 10Sasso et al. Cardiovasc Diabetol  (2016) 15:147 
References
 1. Schramm TK, Gislason GH, Køber L, Rasmussen S, Rasmussen JN, 
Abildstrøm SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-
Pedersen C. Diabetes patients requiring glucose-lowering therapy 
and nondiabetics with a prior myocardial infarction carry the same 
cardiovascular risk: a population study of 3.3 million people. Circulation. 
2008;117(15):1945–54.
 2. Stamler J, Vaccaro O, Neaton JD, Wentworth D, The Multiple Risk Factor 
Intervention Trial Research Group. Diabetes, other risk factors, and 12-yr 
cardiovascular mortality for men screened in the Multiple Risk Factor 
Intervention Trial. Diabetes Care. 1993;16:434–44.
 3. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson 
PW, Alberts MJ, D’Agostino R, Liau CS, Mas JL, Röther J, Smith SC Jr, 
Salette G, Contant CF, Massaro JM. Steg PG; REACH Registry Investigators. 
Comparative determinants of 4-year cardiovascular event rates in stable 
outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350–7.
 4. World Health Organization. Fact sheet No 317: cardiovascular disease. 
2015. http://www.who.int/mediacentre/factsheets/fs317/en/.
 5. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of 
coronary artery disease and the acute coronary syndromes. N Engl J Med. 
1992;326:242–50.
 6. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, 
Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, 
Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, 
Zamorano JL; Authors/Task Force Members. 2016 ESC/EAS guidelines 
for the management of dyslipidaemias: the task force for the manage-
ment of dyslipidaemias of the European Society of Cardiology (ESC) 
and European Atherosclerosis Society (EAS) developed with the special 
contribution of the European Association for Cardiovascular Prevention & 
Rehabilitation (EACPR). Eur Heart J. 2016. doi:10.1093/eurheartj/ehw272.
 7. Aso Y. Cardiovascular disease in patients with diabetic nephropathy. Curr 
Mol Med. 2008;8(6):533–43.
 8. Ted Wu. Cardiovascular disease in diabetic nephropathy patients: cell 
adhesion molecules as potential markers? Vasc Health Risk Manag. 
2005;1(4):309–16.
 9. Czekalski S. Diabetic nephropathy and cardiovascular diseases. Ann Acad 
Med Bialostoc. 2005;50:122.
 10. Kanter JE, Johansson F, LeBoeuf RC, Bornfeldt KE. Do glucose and lipids 
exert independent effects on atherosclerotic lesion initiation or progres-
sion to advanced plaques? Circ Res. 2007;100:769–81.
 11. Cersosimo E, Defronzo RA. Insulin resistance and endothelial dysfunc-
tion: the road map to cardiovascular diseases. Diabetes Metab Res Rev. 
2006;22:423–36.
 12. Ware JA, Heistad DD. Seminars in medicine of the Beth Israel Hos-
pital, Boston. Platelet-endothelium interactions. N Engl J Med. 
1993;328:628–35.
 13. Taskinen MR. Type 2 diabetes as a lipid disorder. Curr Mol Med. 
2005;5:297–308.
 14. Kumar A, Singh V. Atherogenic dyslipidemia and diabetes mellitus: 
what’s new in the management arena? Vasc Health Risk Manag. 
2010;6:665–6699.
 15. Standards of Medical Care in Diabetes. Cardiovascular disease and risk 
management. Diabetes Care. 2016;39(Suppl. 1):S60–71.
 16. Scandinavian Simvastatin Survival Study group. Randomized con-
trolled trial of cholesterol lowering in 4444 patients with coronary 
heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 
1994;344:1383–9.
 17. Sacks F, Pfeffer M, Moye L, Rouleau JL, Rutherford JD, Cole TG, Brown L, 
Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of 
pravastatin on coronary events after myocardial infarction in patients 
with average cholesterol levels. N Engl J Med. 1996;335:1001–9.
 18. The Long-term Intervention with Pravastatin in Ischaemic Heart. 
Disease (LIPID) Study Group. Prevention of cardiovascular events 
and death with pravastatin in patients with coronary heart dis-
ease and a broad range of initial cholesterol levels. N Engl J Med. 
1998;339:1349–57.
 19. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, 
Bertolami MC, Jackson G, Strauss B. Meier B for the Lescol Intervention 
Prevention Study (LIPS) Investigators. JAMA. 2002;287:3215–22.
 20. Abramson J, Wright JM. Are lipid-lowering guidelines evidence based? 
Lancet. 2007;369:168–9.
 21. Savoie I, Kazanjian A. Utilization of lipid-lowering drugs in men and 
women: a reflection of the research evidence? J Clin Epidimiol. 
2002;55:95–101.
 22. Chiuve SE, McCullough ML, Sacks FM, Rimm EB. Healthy lifestyle factors in 
the primary prevention of coronary heart disease among men: benefits 
among users and nonusers of lipid lowering and antihypertensive medi-
cations. Circulaton. 2006;114:160–7.
 23. Manuel DG, Kwong K, Tanuseputro P, Lim J, Mustard CA, Anderson GM, 
Ardal S, Alter DA, Laupacis A. Effectiveness and efficiency of different 
guidelines on statin treatment for preventing deaths from coronary heart 
disease: modeling study. BMJ. 2006;332:1419–22.
 24. Cheung BM. Statins for people with diabetes. Lancet. 2008;371:94–5.
 25. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 
2003;289:1681–90.
 26. Trifirò G, Alacqua M, Corrao S, Tari M, Arcoraci V. Statins for the primary 
prevention of cardiovascular events in elderly patients: a picture from 
clinical practice without strong evidence from clinical trials. J am Ger Soc. 
2008;56:175–7.
 27. Sasso FC, De Nicola L, Carbonara O, Nasti R, Minutolo R, Salvatore T, 
Conte G, Torella R. Cardiovascular risk factors and disease management 
in type 2 diabetic patients with diabetic nephropathy. Diabetes Care. 
2006;29(3):498–503.
 28. Clinical practice recommendation. Standards of Medical Care in Diabetes. 
Diabetes Care. 2014;37:S14–80.
 29. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das 
SR, et al. Heart disease and stroke statistics, 2016 update. A report from 
the American Heart Association. Circulation. 2016;133(4):e38–360.
 30. Sasso FC, Chiodini P, Carbonara O, De Nicola L, Conte G, Salvatore T, Nasti 
R, Marfella R, Gallo C, Signoriello S, Torella R, Minutolo R, Nephropathy In 
Type 2 Diabetes Study Group. High cardiovascular risk in patients with 
Type 2 diabetic nephropathy: the predictive role of albuminuria and 
glomerular filtration rate. The NID-2 Prospective Cohort Study. Nephrol 
Dial Transplant. 2012;27(6):2269–74.
 31. Pugliese G, Solini A, Bonora E, Orsi E, Zerbini G, Fondelli C, Gruden G, Cav-
alot F, Lamacchia O, Trevisan R, Vedovato M, Penno G, RIACE Study Group. 
Distribution of cardiovascular disease and retinopathy in patients with 
type 2 diabetes according to different classification systems for chronic 
kidney disease: a cross-sectional analysis of the renal insufficiency and 
cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol. 
2014;13(13):59.
 32. Cea Soriano L, Johansson S, Stefansson B, Rodríguez LA. Cardiovascular 
events and all-cause mortality in a cohort of 57,946 patients with type 2 
diabetes: associations with renal function and cardiovascular risk factors. 
Cardiovasc Diabetol. 2015;18(14):38.
 33. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for 
recommended low-density lipoprotein treatment targets: a solvable 
problem. Ann Intern Med. 2006;145:520–30.
 34. Bruckert E, Ferrières J. Evidence supporting primary prevention of cardio-
vascular diseases with statins: gaps between updated clinical results and 
actual practice. Arch Cardiovasc Dis. 2014;107(3):188–200.
 35. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary 
prevention of coronary heart disease: meta-analysis of randomized trials. 
BMJ. 2000;321:983–6.
 36. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N. Statins 
and all-cause mortality in high-risk primary prevention. A meta-analysis 
of 11 randomized controlled trials involving 65229 participants. Arch 
Intern Med. 2010;170:1024–32.
 37. Taylor FC, et al. Statins for the primary prevention of cardiovascular 
disease. Cochrane Database Sys Rev. 2013;310:2451.
 38. Beishuizen ED, Van De Ree MA, Jukema JW, et al. Two year statin therapy 
does not alter the progression of intima medica thickness in patients 
with type 2 diabetes without manifest cardiovascular disease. Diabetes-
Care. 2004;27(12):2887–91.
 39. Heart Protection Study Collaborative Group. MRC/BHF Heart Protec-
tion Study of cholesterol-lowering with simvastatin in 5963 peo-
ple with diabetes: a randomised placebo-controlled trial. Lancet. 
2003;361:2005–16.
 40. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane 
PW, McKillop JH, Packard CJ. Prevention of coronary heart disease 
with pravastatin in men with hypercholesterolemia. N Engl J Med. 
1995;333:1301–7.
Page 10 of 10Sasso et al. Cardiovasc Diabetol  (2016) 15:147 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 41. Ford I, Murray H, McCowan C, Packard CJ. Long term safety and efficacy 
of lowering LDL cholesterol with statin therapy: 20-year Follow-Up of 
West of Scotland Coronary Prevention Study. Circulation. 2016. [Epub 
ahead of print].
 42. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, 
Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of 
acute coronary events with lovastatin in men and women with average 
cholesterol levels: results of AFCAPS/TexCAPS, Air Force/Texas coronary 
atherosclerosis prevention study. JAMA. 1998;279:1615–22.
 43. Colombo MG, Meisinger C, Amann U, Heier M, von Scheidt W, Kuch B, 
Peters A, Kirchberger I. Association of obesity and long-term mortality 
in patients with acute myocardial infarction with and without diabetes 
mellitus: results from the MONICA/KORA myocardial infarction registry. 
Cardiovasc Diabetol. 2015;18(14):24.
 44. Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of ator-
vastatin in the prevention of cardiovascular end points in subject with 
type 2 diabetes the Atorvastatin Study for Prevention of Coronary Heart 
Desease Endpoints in Non-Insulin-Dependent-Diabetes-Mellitus (ASPEN). 
Diabetes Care. 2006;29:1478–85.
 45. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, 
Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, 
CARDS investigators. Primary prevention of cardiovascular disease with 
atorvastatin in type 2 diabetes in the Collaborative Atorvastatin diabetes 
Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 
2004;364:685–96.
 46. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins 
R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, 
O’Brien E, Ostergren J, ASCOT investigators. Prevention of coronary 
and stroke events with atorvastatin in hypertensive patients who 
have average or lower-than-average cholesterol concentrations, 
in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering 
Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet. 
2003;361(9364):1149–58.
 47. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR. ASCOT 
Investigators The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year 
mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J. 
2011;32(20):2525–32.
 48. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford 
I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, 
Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westen-
dorp RG, PROSPER study group. PROspective Study of Pravastatin in the 
Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease 
(PROSPER): a randomized controlled trial. Lancet. 2002;360:1623–30.
 49. Lloyd SM, Stott DJ, de Craen AJ, Kearney PM, Sattar N, Perry I, Packard CJ, 
Briggs A, Marchbank L, Comber H, Jukema JW, Westendorp RG, Trompet 
S, Buckley BM, Ford I. Long-term effects of statin treatment in elderly 
people: extended follow-up of the PROspective Study of Pravastatin in 
the Elderly at Risk (PROSPER). PLoS ONE. 2013;8(9):e72642.
 50. ALLHAT-LLT Collaborative Research Group. Major outcomes in moder-
ately hypercholesterolemic, hypertensive patients randomized to pravas-
tatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998–3007.
 51. Mansi IA, English J, Zhang S, Mortensen EM, Halm EA. Long-term out-
comes of short-term statin use in healthy adults: a retrospective cohort 
study. Drug Saf. 2016;39(6):543–59.
 52. Lim S, Oh PC, Sakuma I, Koh KK. How to balance cardiorenometabolic 
benefits and risks of statins. Atherosclerosis. 2014;235(2):644–8.
